I'm increasingly satisfied that this ship is navigating a much sharper course towards some form of commercialisation event, I just don't know who's up on the bridge.
We must find out soon.
Hard to guess the timing of corporate things, but given a focus of big pharma on drug development things like 'biobetters' and 'biosuperiors', (thanks Hottod) we shouldn't be surprised if something from left field happened anytime, primarily based on the PYC peptide library and what it could potentially mean $$$'s improving the market capitalisation and activity of drug development sections of a really big boy.
I'd be happy to trade my PYC shares for some scrip in a really big boy, if the price was (very) right.
That new iv data sounds great, and must surely attract more industry enquiry and NDA's as well
Dr Hockings will be more than aware that with his huge holding, there is only one exit opportunity for him ... and it is a strategic exit.
Genetech must still be around the table, so maybe the next interesting news comes from that direction.
On that recent market turnover action - can't any Perth shareholder with some spare time physically visit (to inspect) the full PYC share registry?, and they could then summarise any changes to that top 50 that was disclosed in the statutory accounts a month or so ago?
PYC Price at posting:
1.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)